Assessment of 4D 18F-FDG PET-CT in Radiotherapy for Non Small Cell Lung Cancers (PULMOTEP)
|ClinicalTrials.gov Identifier: NCT01421953|
Recruitment Status : Completed
First Posted : August 23, 2011
Last Update Posted : October 23, 2014
|Condition or disease||Intervention/treatment||Phase|
|Lung Cancer Non-small-cell Lung Carcinoma||Device: CT-simulation and 4D PET-CT||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||7 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Supportive Care|
|Official Title:||Assessment of Four-dimensional (4D) 18F-fluoro-deoxy-glucose (FDG) Positron Emission Tomography and Computed Tomography System (PET-CT) in Radiotherapy for Non Small Cell Lung Cancers (NSCLC)|
|Study Start Date :||August 2011|
|Actual Primary Completion Date :||November 2012|
|Actual Study Completion Date :||November 2012|
Device: CT-simulation and 4D PET-CT
Patients will do a CT-simulation and 4D PET-CT in radiotherapy treatment position. The target volumes and the dosimetries obtained with both modalities will be compared.
- Quantitative and qualitative differences between CT-simulation and 4D PET-CT volumes [ Time Frame: between day 7 and day 21 after inclusion ]
Quantitative and qualitative differences between the radiotherapy target volumes obtained from CT-simulation and from 4D-PET-CT.
The quantitative difference is expressed as a percentage of the total volume defined on CT simulation.
The qualitative difference is defined as the volumes defined only on CT-simulation or only on 4D-PET-CT, expressed as a percentage of the total volume defined on CT-simulation.
- Dosimetrics differences between the dosimetries obtained from CT-simulation or from 4D-PET-CT. [ Time Frame: between day 7 and day 21 after inclusion ]
- Search of predictive criteria (histology, tumour localization, TNM staging) for 4D-PET-CT impact on the radiotherapy target volumes and on the dosimetries. [ Time Frame: between day 7 and day 21 after inclusion ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01421953
|CHU Bordeaux - hôpital Pellegrin|
|Bordeaux, France, 33000|
|Principal Investigator:||Philippe FERNANDEZ, Pr||University Hospital, Bordeaux, France|